Search Results

Tivantinib 5 mg  | 99.95%

TargetMol

Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.

More Information Supplier Page

Tivantinib 50 mg  | 99.95%

TargetMol

Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.

More Information Supplier Page

Tivantinib 25 mg  | 99.95%

TargetMol

Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.

More Information Supplier Page

Tivantinib 10 mg  | 99.95%

TargetMol

Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.

More Information Supplier Page

PHA-665752 50 mg  | 99.35%

TargetMol

PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.

More Information Supplier Page

PHA-665752 5 mg  | 99.35%

TargetMol

PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.

More Information Supplier Page

Tirbanibulin 10 mg  | 99.67%

TargetMol

Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

More Information Supplier Page

Tirbanibulin 100 mg  | 99.67%

TargetMol

Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

More Information Supplier Page

Tosedostat 5 mg  | Purity Not Available

TargetMol

CHR-2797 is an orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid […]

More Information Supplier Page

Tosedostat 2 mg  | Purity Not Available

TargetMol

CHR-2797 is an orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid […]

More Information Supplier Page